Demonstration of safety of probiotics: A review

Seppo Salminen, Atte von Wright, Lorenzo Morelli, Philippe Marteau, Dominique Brassard, Willem M. de Vos, Rangne Fonden, Maija Saxelin, Kevin Collins, Gunnar Mogensen, Stein-Erik Birkeland, Tiina Mattila-Sandholm

Research output: Contribution to journalReview ArticleScientificpeer-review

563 Citations (Scopus)

Abstract

Probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that exhibit a beneficial effect on the health of the host when they are ingested. They are used in foods, especially in fermented dairy products, but also in pharmaceutical preparations. The development of new probiotic strains aims at more active beneficial organisms. In the case of novel microorganisms and modified organisms the question of their safety and the risk to benefit ratio have to be assessed. Lactic acid bacteria (LAB) in foods have a long history of safe use.
Members of the genera Lactococcus and Lactobacillus are most commonly given generally-recognised-as-safe (GRAS) status whilst members of the genera Streptococcus and Enterococcus and some other genera of LAB contain some opportunistic pathogens. Lactic acid bacteria are intrinsically resistant to many antibiotics. In many cases resistances are not, however, transmissible, and the species are also sensitive to many clinically used antibiotics even in the case of a lactic acid bacteria- associated opportunistic infection. Therefore no particular safety concern is associated with intrinsic type of resistance.
Plasmid-associated antibiotic resistance, which occasionally occurs, is another matter because of the possibility of the resistance spreading to other, more harmful species and genera. The transmissible enterococcal resistance against glycopeptide antibiotics (vancomycin and teicoplanin) is particularly noteworthy, as vancomycin is one of the last effective antibiotics left in the treatment of certain multidrug-resistant pathogens.
New species and more specific strains of probiotic bacteria are constantly identified. Prior to incorporating new strains into products their efficacy should be carefully assessed, and a case by case evaluation as to whether they share the safety status of traditional food-grade organisms should be made. The current documentation of adverse effects in the literature is reviewed. Future recommendations for the safety of already existing and new probiotics will be given.
Original languageEnglish
Pages (from-to)93-106
JournalInternational Journal of Food Microbiology
Volume44
Issue number1-2
DOIs
Publication statusPublished - 1998
MoE publication typeA2 Review article in a scientific journal

Fingerprint

Probiotics
probiotics
lactic acid bacteria
antibiotics
Bacteria
Safety
vancomycin
Lactic Acid
Anti-Bacterial Agents
beneficial organisms
Vancomycin
fermented dairy products
glycopeptides
microorganisms
Food
Lactococcus
food grades
pathogens
traditional foods
bacteria

Cite this

Salminen, S., Wright, A. V., Morelli, L., Marteau, P., Brassard, D., de Vos, W. M., ... Mattila-Sandholm, T. (1998). Demonstration of safety of probiotics: A review. International Journal of Food Microbiology, 44(1-2), 93-106. https://doi.org/10.1016/S0168-1605(98)00128-7
Salminen, Seppo ; Wright, Atte von ; Morelli, Lorenzo ; Marteau, Philippe ; Brassard, Dominique ; de Vos, Willem M. ; Fonden, Rangne ; Saxelin, Maija ; Collins, Kevin ; Mogensen, Gunnar ; Birkeland, Stein-Erik ; Mattila-Sandholm, Tiina. / Demonstration of safety of probiotics : A review. In: International Journal of Food Microbiology. 1998 ; Vol. 44, No. 1-2. pp. 93-106.
@article{5eb84c359c494e6a800e0f2c0c427c0e,
title = "Demonstration of safety of probiotics: A review",
abstract = "Probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that exhibit a beneficial effect on the health of the host when they are ingested. They are used in foods, especially in fermented dairy products, but also in pharmaceutical preparations. The development of new probiotic strains aims at more active beneficial organisms. In the case of novel microorganisms and modified organisms the question of their safety and the risk to benefit ratio have to be assessed. Lactic acid bacteria (LAB) in foods have a long history of safe use. Members of the genera Lactococcus and Lactobacillus are most commonly given generally-recognised-as-safe (GRAS) status whilst members of the genera Streptococcus and Enterococcus and some other genera of LAB contain some opportunistic pathogens. Lactic acid bacteria are intrinsically resistant to many antibiotics. In many cases resistances are not, however, transmissible, and the species are also sensitive to many clinically used antibiotics even in the case of a lactic acid bacteria- associated opportunistic infection. Therefore no particular safety concern is associated with intrinsic type of resistance. Plasmid-associated antibiotic resistance, which occasionally occurs, is another matter because of the possibility of the resistance spreading to other, more harmful species and genera. The transmissible enterococcal resistance against glycopeptide antibiotics (vancomycin and teicoplanin) is particularly noteworthy, as vancomycin is one of the last effective antibiotics left in the treatment of certain multidrug-resistant pathogens. New species and more specific strains of probiotic bacteria are constantly identified. Prior to incorporating new strains into products their efficacy should be carefully assessed, and a case by case evaluation as to whether they share the safety status of traditional food-grade organisms should be made. The current documentation of adverse effects in the literature is reviewed. Future recommendations for the safety of already existing and new probiotics will be given.",
author = "Seppo Salminen and Wright, {Atte von} and Lorenzo Morelli and Philippe Marteau and Dominique Brassard and {de Vos}, {Willem M.} and Rangne Fonden and Maija Saxelin and Kevin Collins and Gunnar Mogensen and Stein-Erik Birkeland and Tiina Mattila-Sandholm",
year = "1998",
doi = "10.1016/S0168-1605(98)00128-7",
language = "English",
volume = "44",
pages = "93--106",
journal = "International Journal of Food Microbiology",
issn = "0168-1605",
publisher = "Elsevier",
number = "1-2",

}

Salminen, S, Wright, AV, Morelli, L, Marteau, P, Brassard, D, de Vos, WM, Fonden, R, Saxelin, M, Collins, K, Mogensen, G, Birkeland, S-E & Mattila-Sandholm, T 1998, 'Demonstration of safety of probiotics: A review', International Journal of Food Microbiology, vol. 44, no. 1-2, pp. 93-106. https://doi.org/10.1016/S0168-1605(98)00128-7

Demonstration of safety of probiotics : A review. / Salminen, Seppo; Wright, Atte von; Morelli, Lorenzo; Marteau, Philippe; Brassard, Dominique; de Vos, Willem M.; Fonden, Rangne; Saxelin, Maija; Collins, Kevin; Mogensen, Gunnar; Birkeland, Stein-Erik; Mattila-Sandholm, Tiina.

In: International Journal of Food Microbiology, Vol. 44, No. 1-2, 1998, p. 93-106.

Research output: Contribution to journalReview ArticleScientificpeer-review

TY - JOUR

T1 - Demonstration of safety of probiotics

T2 - A review

AU - Salminen, Seppo

AU - Wright, Atte von

AU - Morelli, Lorenzo

AU - Marteau, Philippe

AU - Brassard, Dominique

AU - de Vos, Willem M.

AU - Fonden, Rangne

AU - Saxelin, Maija

AU - Collins, Kevin

AU - Mogensen, Gunnar

AU - Birkeland, Stein-Erik

AU - Mattila-Sandholm, Tiina

PY - 1998

Y1 - 1998

N2 - Probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that exhibit a beneficial effect on the health of the host when they are ingested. They are used in foods, especially in fermented dairy products, but also in pharmaceutical preparations. The development of new probiotic strains aims at more active beneficial organisms. In the case of novel microorganisms and modified organisms the question of their safety and the risk to benefit ratio have to be assessed. Lactic acid bacteria (LAB) in foods have a long history of safe use. Members of the genera Lactococcus and Lactobacillus are most commonly given generally-recognised-as-safe (GRAS) status whilst members of the genera Streptococcus and Enterococcus and some other genera of LAB contain some opportunistic pathogens. Lactic acid bacteria are intrinsically resistant to many antibiotics. In many cases resistances are not, however, transmissible, and the species are also sensitive to many clinically used antibiotics even in the case of a lactic acid bacteria- associated opportunistic infection. Therefore no particular safety concern is associated with intrinsic type of resistance. Plasmid-associated antibiotic resistance, which occasionally occurs, is another matter because of the possibility of the resistance spreading to other, more harmful species and genera. The transmissible enterococcal resistance against glycopeptide antibiotics (vancomycin and teicoplanin) is particularly noteworthy, as vancomycin is one of the last effective antibiotics left in the treatment of certain multidrug-resistant pathogens. New species and more specific strains of probiotic bacteria are constantly identified. Prior to incorporating new strains into products their efficacy should be carefully assessed, and a case by case evaluation as to whether they share the safety status of traditional food-grade organisms should be made. The current documentation of adverse effects in the literature is reviewed. Future recommendations for the safety of already existing and new probiotics will be given.

AB - Probiotics are commonly defined as viable microorganisms (bacteria or yeasts) that exhibit a beneficial effect on the health of the host when they are ingested. They are used in foods, especially in fermented dairy products, but also in pharmaceutical preparations. The development of new probiotic strains aims at more active beneficial organisms. In the case of novel microorganisms and modified organisms the question of their safety and the risk to benefit ratio have to be assessed. Lactic acid bacteria (LAB) in foods have a long history of safe use. Members of the genera Lactococcus and Lactobacillus are most commonly given generally-recognised-as-safe (GRAS) status whilst members of the genera Streptococcus and Enterococcus and some other genera of LAB contain some opportunistic pathogens. Lactic acid bacteria are intrinsically resistant to many antibiotics. In many cases resistances are not, however, transmissible, and the species are also sensitive to many clinically used antibiotics even in the case of a lactic acid bacteria- associated opportunistic infection. Therefore no particular safety concern is associated with intrinsic type of resistance. Plasmid-associated antibiotic resistance, which occasionally occurs, is another matter because of the possibility of the resistance spreading to other, more harmful species and genera. The transmissible enterococcal resistance against glycopeptide antibiotics (vancomycin and teicoplanin) is particularly noteworthy, as vancomycin is one of the last effective antibiotics left in the treatment of certain multidrug-resistant pathogens. New species and more specific strains of probiotic bacteria are constantly identified. Prior to incorporating new strains into products their efficacy should be carefully assessed, and a case by case evaluation as to whether they share the safety status of traditional food-grade organisms should be made. The current documentation of adverse effects in the literature is reviewed. Future recommendations for the safety of already existing and new probiotics will be given.

U2 - 10.1016/S0168-1605(98)00128-7

DO - 10.1016/S0168-1605(98)00128-7

M3 - Review Article

VL - 44

SP - 93

EP - 106

JO - International Journal of Food Microbiology

JF - International Journal of Food Microbiology

SN - 0168-1605

IS - 1-2

ER -

Salminen S, Wright AV, Morelli L, Marteau P, Brassard D, de Vos WM et al. Demonstration of safety of probiotics: A review. International Journal of Food Microbiology. 1998;44(1-2):93-106. https://doi.org/10.1016/S0168-1605(98)00128-7